Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia

References

• Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol. 2021 Jan;96(1):145–162.
   PubMed Web of Science ®Google Scholar
• Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014 Jun;89(6):581–587.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018 Feb 9;8(2):15.
   PubMedGoogle Scholar
• Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008 Feb;22(2):437–438.
   PubMed Web of Science ®Google Scholar
• Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015 Oct;90(10):864–870.
   PubMed Web of Science ®Google Scholar
• Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012 Nov 20;30(33):4098–4103.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Koschmieder S, Foltz L, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. Ann Hematol. 2017 Oct;96(10):1653–1665.
   PubMed Web of Science ®Google Scholar
• Mesa R, Miller CB, Thyne M, et al. Myeloproliferative neoplasms (MPNs) have a significant impact on patients’ overall health and productivity: the MPN Landmark survey. BMC Cancer. 2016 Feb 27;16:167.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 Mar 26;113(13):2895–2901.
   PubMed Web of Science ®Google Scholar
• Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. Hemasphere. 2017 Dec;1(1):e1.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012 Jan;87(1):25–33.
   PubMed Web of Science ®Google Scholar
• Masarova L, Alhuraiji A, Bose P, et al. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Eur J Haematol. 2018 Mar;100(3):257–263.
   PubMed Web of Science ®Google Scholar
• Masarova L, Mesa RA, Hernandez-Boluda JC, et al. Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. Leuk Res. 2020 Apr;91:106338.
   PubMed Web of Science ®Google Scholar
• Marcellino BK, Verstovsek S, Mascarenhas J. The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):415–421.
   PubMed Web of Science ®Google Scholar
• TriNetX. Dataworks US EMR database [cited Apr 2022]. Available from: https://trinetx.com/
   Google Scholar
• Tam CS, Kantarjian H, Cortes J, et al. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009 Nov 20;27(33):5587–5593.
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda JC, Correa JG, Alvarez-Larran A, et al. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. Br J Haematol. 2018 May;181(3):397–400.
   PubMed Web of Science ®Google Scholar
• Scotch AH, Kosiorek H, Scherber R, et al. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. Leuk Res. 2017 Dec;63:34–40.
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1 29(4):392–397.
   PubMed Web of Science ®Google Scholar
• Gerds AT, Gotlib J, Bose P. et al. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology Myeloproliferative Neoplasms. Version 3.2022. [cited 2 Jun 2022]. Available from: Accessed 02 Jun 2022 https://www.nccn.org/guidelines/recently-published-guidelines. Version 3.2022.
   Google Scholar
• Tamari R, Mughal TI, Rondelli D, et al. Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? Bone Marrow Transplant. 2015 May 1;50(5):628–636.
   PubMed Web of Science ®Google Scholar
• Incyte corporation. JAKAFI® (ruxolitinib) US Prescribing Information; 2021 https://www.jakafi.com/?utm_source=google&utm_medium=cpc&utm_campaign=JAK-DTC_22_BR_Jakafi_Phrase__%3BS%3BPH%3BBR%3BHEM%3BDTC%3BBR&utm_content=Jakafi_Treatment_P&utm_term=jakafi+treatment&gclsrc=aw.ds&&gclid=EAIaIQobChMI0d6c54vO-QIVRgytBh04HAiFEAAYASAAEgI8Y_D_BwE.
   Google Scholar
• Celgene Corporation INREBIC® (fedratinib) US Prescribing Information; 2021. Celgene.
   Google Scholar
• CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia [Internet]. Feb 28, 2022 [cited June 7, 2022]. [Internet]. Feb 28, 2022: https://investors.ctibiopharma.com/news-releases/news-release-details/cti-biopharma-announces-fda-accelerated-approval-vonjotm
   Google Scholar
• Venugopal S, Mascarenhas J. Current clinical investigations in myelofibrosis. Hematol Oncol Clin North Am. 2021 Apr;35(2):353–373.
   PubMed Web of Science ®Google Scholar
• FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions [Internet]. Sep 1, 2021 cited Jul 20, 2022]. [Internet]. Sep 1, 2021: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death
   Google Scholar
• CTI BioPharma Corp. VONJO^TM (pacritinib) US prescribing information. 2022.
   Google Scholar
• Singer JW, Al-Fayoumi S, Ma H, et al. Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor. J Exp Pharmacol. 2016;8:11–19.
   PubMedGoogle Scholar
• CTI BioPharma Corp. Data on file - preclinical data report. 2022.
   Google Scholar
• Mascarenhas J, Gerds A, Kiladjian JJ, et al. MPN-038: PACIFICA: a randomized, controlled phase 3 study of pacritinib versus physician’s choice in patients with primary or secondary myelofibrosis and severe thrombocytopenia. Clinical Lymphoma Myeloma and Leukemia. 2021Sep 01;21: S352–S353.
   Web of Science ®Google Scholar
• Quintás-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010 Apr 15;115(15):3109–3117.
   PubMed Web of Science ®Google Scholar
• FDA Approves Incyte’s JakafiTM (ruxolitinib) for Patients with Nyelofibrosis. [cited 2011 Nov 11]. Available from: https://investor.incyte.com/news-releases/news-release-details/fda-approves-incytes-jakafitm-ruxolitinib-patients-myelofibrosis
   Google Scholar
• Harrison CN, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):787–798.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. [2012 Mar 1];366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Kiladjian JJ. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia. 2021 Jan;35(1):1–17.
   PubMed Web of Science ®Google Scholar
• U.S. FDA Approves INREBIC® (Fedratinib) as first new treatment in nearly a decade for patients with myelofibrosis [Internet] Aug 16, 2019. [cited 2022 Jun 7]. https://ir.celgene.com/press-releases-archive/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx
   Google Scholar
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients (MOMENTUM). 2019 [cited 2022 Jun 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT04173494
   Google Scholar
• Asshoff M, Petzer V, Warr MR, et al. Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. Blood. 2017 Mar 30 129(13):1823–1830.
   PubMed Web of Science ®Google Scholar
• Azhar M, Kincaid Z, Kesarwani M, et al. Momelotinib is a highly potent inhibitor of FLT3-mutant AML. Blood Adv. 2022 Feb 22;6(4):1186–1192.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis. N Eng J Med. 2010 [2010 Sep 16];363(12):1117–1127.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. J Hematol Oncol. 2017 Sep 29 10(1):156.
   PubMedGoogle Scholar
• Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 Oct 29 6(1):81.
   PubMedGoogle Scholar
• Al-Ali HK, Griesshammer M, Foltz L, et al. Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts. Br J Haematol. 2020 Jun;189(5):888–903.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Te Boekhorst PAW, Harrison CN, et al. EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. Haematologica. 2019 May;104(5):947–954.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Prchal J, Afrin L, et al. Safety and Efficacy of Ruxolitinib in Patients with Myelofibrosis and Low Platelet Counts (50 - 100 × 109/L): Final Analysis of an Open-Label Phase 2 Study. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):336–346.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (Jakarta-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017 July;4(7):e317–e324.
   PubMed Web of Science ®Google Scholar
• Pardanani A, Harrison CN, Cortes JE, et al. Safety and Efficacy of Fedratinib in Patients with Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug;1(5):643–651.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: an updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020 Jun;95(6):594–603.
   PubMed Web of Science ®Google Scholar
• Vianelli N, Benevolo G, Vannucchi A, et al. A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). Blood. 2021;138(Supplement 1):3643.
   Google Scholar
• Gupta V, Yacoub A, Verstovsek S, et al. Safety and tolerability results from the phase 3b FREEDOM trial of fedratinib (FEDR), an oral, selective JAK2 inhibitor, in patients with myelofibrosis (MF) previously treated with ruxolitinib (RUX). Presented at EHA 2022.
   Google Scholar
• Tyner JW, Bumm TG, Deininger J, et al. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood. 2010 Jun 24 115(25):5232–5240.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Platzbecker U, et al. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Lancet Haematol. 2018 Feb;5(2):e73–e81.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Kiladjian JJ, Catalano JV, et al. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. J Clin Oncol. 2017 Dec 1 35(34):3844–3850.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Gerds AT, Vannucchi A, et al. MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor. J Clin Oncol. 2022;40(Suppl 16):7002. Abstract.
   Google Scholar
• Sierra OncologyAnnounces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis Jan 25, 2022 [cited 2022 Jun 7]. Jan 25, 2022: https://investor.sierraoncology.com/news-releases/news-details/2022/Sierra-Oncology-Announces-Momelotinib-Achieved-Statistically-Significant-Benefit-on-Symptoms-Anemia-and-Splenic-Size-in-the-Pivotal-MOMENTUM-Study-for-Myelofibrosis/default.aspx
   Google Scholar
• Gerds AT, Verstovsek S, Vannucchi A, et al. Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM]. J Clin Oncol. 2022;40(Suppl 16):7061. Abstract.
   Google Scholar
• Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci. 2018 Dec;27(12):1984–2009.
   PubMed Web of Science ®Google Scholar
• Rah B, Rather RA, Bhat GR, et al. JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies. Front Pharmacol. 2022;13:821344.
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 Feb 9; 129(6):667–679.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Huang J, et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival. Leukemia. 2008 Apr;22(4):756–761.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Barosi G, Specchia G, et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood. 2009 Aug 20 114(8):1477–1483.
   Google Scholar
• Passamonti F, Rumi E. Clinical relevance of JAK2 (V617F) mutant allele burden. Haematologica. 2009 Jan;94(1):7–10.
   PubMed Web of Science ®Google Scholar
• Balka KR, De Nardo D. Understanding early TLR signaling through the myddosome. J Leukoc Biol. 2019 Feb;105(2):339–351.
   PubMed Web of Science ®Google Scholar
• Fisher DAC, Miner CA, Engle EK, et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFkappaB signaling. Leukemia. 2019 Aug;33(8):1978–1995.
   PubMed Web of Science ®Google Scholar
• Lai HY, Brooks SA, Craver BM, et al. Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm. Blood Adv. 2019 Jan 22 3(2):122–131.
   PubMed Web of Science ®Google Scholar
• Leimkuhler NB, Gleitz HFE, Ronghui L, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2021 Apr 1;28(4):637–652e8.
   PubMed Web of Science ®Google Scholar
• Mager LF, Riether C, Schurch CM, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015 Jul 1;125(7):2579–2591.
   PubMed Web of Science ®Google Scholar
• Basiorka AA, McGraw KL, Eksioglu EA, et al. The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype. Blood. 2016 Dec 22;128(25):2960–2975.
   PubMed Web of Science ®Google Scholar
• Singer JW, Fleischman A, Al-Fayoumi S, et al. Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy. Oncotarget. 2018 Sep 7;9(70):33416–33439.
   PubMedGoogle Scholar
• Mascarenhas J, Hoffman R, Talpaz M, et al. Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2018 May 1;4(5):652–659.
   PubMed Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, et al. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies. Leukemia. 2011 Nov;25(11):1751–1759.
   PubMed Web of Science ®Google Scholar
• Mullally A, Hood J, Harrison C, et al. Fedratinib in myelofibrosis. Blood Adv. 2020 Apr 28 4(8):1792–1800.
   PubMed Web of Science ®Google Scholar
• Fedratinib NDA 2019 [cited 2022 Jun 7]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf
   Google Scholar
• Jarocha DJ, Gadue P, Tong W, et al. Janus Kinase (Jak) 1 Inhibition Affects Both Megakaryopoiesis and Thrombopoiesis. Blood. 2018;132(Supplement 1):2559.
   Google Scholar
• Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017 May;4(5):e225–e236.
   PubMed Web of Science ®Google Scholar
• Komrokji RS, Seymour JF, Roberts AW, et al. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis. Blood. 2015 Apr 23 125(17):2649–2655.
   PubMed Web of Science ®Google Scholar
• Hosseini MM, Kurtz SE, Abdelhamed S, et al. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes. Leukemia. 2018 Nov;32(11):2374–2387.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Nicolosi M, Mudireddy M, et al. Driver mutations and prognosis in primary myelofibrosis: mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018 Mar;93(3):348–355.
   PubMed Web of Science ®Google Scholar
• Al-Fayoumi S, Watson R,O, Mahoney A, et al. Comparative biomarker profiles of pacritinib, momelotinib, pexidartinib, and ruxolitinib using biomap diversity plus panel. Eur J Cancer. 2016;69:S136.
   Web of Science ®Google Scholar
• Hart S, Goh KC, Novotny-Diermayr V, et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia. Blood Cancer J. 2011 Nov;1(11):e44.
   PubMedGoogle Scholar
• O’Sullivan JM, Harrison CN. JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms. Mol Cell Endocrinol. 2017 Aug 15; 451:71–79
   PubMed Web of Science ®Google Scholar
• Cleary MM, Thompson R, Mahmood S, et al. Pacritinib, a dual FLT3/JAK2 inhibitor, reduces irak-1 signaling in acute myeloid leukemia. Blood. 2015;126(23):570.
   PubMedGoogle Scholar
• Huang Y, Li T, Sane DC, et al. IRAK1 serves as a novel regulator essential for lipopolysaccharide-induced interleukin-10 gene expression. J Biol Chem. 2004 Dec 3 279(49):51697–51703.
   PubMed Web of Science ®Google Scholar
• Al-Fayoumi S, Amberg S, Zhou H, et al. Abstract CT159: investigation of the absorption, metabolism, excretion, and mass balance of [14C]-pacritinib in healthy subjects: a phase I study. Cancer Res. 2016;76(14_Supplement):CT159–CT159.
   Google Scholar
• Gerds AT, Savona MR, Scott BL, et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020 Nov 24;4(22):5825–5835.
   PubMed Web of Science ®Google Scholar
• Venugopal S, Mascarenhas J. The Odyssey of pacritinib in myelofibrosis. Blood Adv. 2022 May 27
   Google Scholar
• Verstovsek S, Odenike O, Singer JW, et al. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. J Hematol Oncol. 2016 Dec 08;9(1):137.
   PubMed Web of Science ®Google Scholar
• Al-Fayoumi SWL, Li H, Wada R, et al. Exposure-response analysis for pacritinib (SB1518), a novel oral JAK2/FLT3 inhibitor, in patients with myelofibrosis. Blood. 2013;122. abstract 4080.
   Google Scholar
• A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis PPVM, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA) (NCT03165734). 2017 [cited Jun 7, 2022]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03165734
   Google Scholar
• CTI BioPharma Corp. Data on File - Clinical Study Report: PAC325 (PERSIST–1). 2016.
   Google Scholar
• Palmer JM, Mesa RA, Oh ST, et al., The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the PERSIST-2 Study. Blood. 2021;138(Supplement 1): 3628.
   Google Scholar
• CTI BioPharma Corp. Data on file - clinical study report: PAC326 (PERSIST–2). 2016.
   Google Scholar
• Gale RP, Barosi G, Barbui T, et al. What are RBC-transfusion-dependence and -Independence? Leuk Res. 2011 Jan;35(1):8–11.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Bose P, Kiladjian -J-J, et al., A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia. Blood. 2021;138(Supplement 1): 3639.
   Google Scholar
• Tremblay D, Mesa R, Scott B, et al. Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2V617F allele burden. Blood Adv. 2020 Dec 8 4(23):5929–5935.
   Google Scholar
• Barosi G, Klersy C, Villani L, et al. JAK2(V617F) allele burden ≥50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy. Leukemia. 2016 Aug;30(8):1772–1775.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa R, Talpaz M, et al. Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia. Haematologica. 2021 Sep 23
   Web of Science ®Google Scholar
• Pemmaraju N, Scott B, Savona M, et al. Risk-Adjusted Safety Analysis of Pacritinib (PAC) in Patients (Pts) with Myelofibrosis (MF). J Clin Oncol. 2022;40(Suppl 16):7058. Abstract.
   Google Scholar
• Mascarenhas J, Harrison CN, Gerds AT, et al. Safety Analysis of Pacritinib in Patients with Myelofibrosis and Severe Thrombocytopenia. Blood. 2021;138(Supplement 1):3640.
   Google Scholar
• Mascarenhas J, Gerds A, Verstovsek S. Paradigm shift: combination BET and JAK inhibition in myelofibrosis. Leukemia. 2021 Dec 01;35(12):3361–3363.
   PubMed Web of Science ®Google Scholar
• Lu M, Xia L, Elmansy N, et al. Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells. Leukemia. 2022 Mar 01;36(3):733–745.
   PubMed Web of Science ®Google Scholar